Risvodetinib

Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD[1][2][3][4].

Product Specifications

CAS Number

[2031185-00-7]

Product Name Alternative

IkT-148009

UNSPSC

12352005

Target

Bcr-Abl; c-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/risvodetinib.html

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(CN2CCN(CC2)C)C=C1)NC3=CC=C(C)C(NC4=NC(C5=CN=CC(C6=C(C)C=NO6)=C5)=CC=N4)=C3

Molecular Formula

C33H34N8O2

Molecular Weight

574.68

References & Citations

[1]Werner MH, et al. Preparation of N-[3-[[4- (2-pyridyl) pyrimidin-2-yl]amino]phenyl]-4-[ (piperazin-1-yl) methyl]benzamide derivatives as inhibitors of kinases: World Intellectual Property Organization, WO2016172528. 2016-10-27.|[2]WHO Drug Information-World Health Organization (WHO) .|[3]Karuppagounder SS, et al. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease. Sci Transl Med. 2023 Jan 18;15 (679) :eabp9352.|[4]Werner MH, Olanow CW. Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity[J]. Mov Disord. 2022 Jan;37 (1) :6-15.